BiotechTube

MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postbariatric Hypoglycemia

Conditions

Postbariatric Hypoglycemia

Trial Timeline

Sep 18, 2023 → Dec 5, 2024

NCT ID
NCT06036784

About MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)

MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C) is a phase 1 stage product being developed by MBX Biosciences for Postbariatric Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT06036784. Target conditions include Postbariatric Hypoglycemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06036784Phase 1Completed

Competing Products

1 competing product in Postbariatric Hypoglycemia

See all competitors
ProductCompanyStageHype Score
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
47

Other Products from MBX Biosciences

MBX 2109Phase 2
47
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionPhase 2
47
MBX 1416 (INN imapextide)Phase 2
47
MBX 4291 + PlaceboPhase 1
28
MBX 2109 (Part A) + MBX 2109 (Part B) + PlaceboPhase 1
28